171 related articles for article (PubMed ID: 16091019)
1. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
Sculpher M; Claxton K
Value Health; 2005; 8(4):433-46. PubMed ID: 16091019
[TBL] [Abstract][Full Text] [Related]
2. Balancing early access with uncertainties in evidence for drugs authorized by prospective case series - systematic review of reimbursement decisions.
Wallerstedt SM; Henriksson M
Br J Clin Pharmacol; 2018 Jun; 84(6):1146-1155. PubMed ID: 29381234
[TBL] [Abstract][Full Text] [Related]
3. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
4. Exploring uncertainty in cost-effectiveness analysis.
Claxton K
Pharmacoeconomics; 2008; 26(9):781-98. PubMed ID: 18767898
[TBL] [Abstract][Full Text] [Related]
5. Role of economic evidence in coverage decision-making in South Korea.
Bae EY; Kim HJ; Lee HJ; Jang J; Lee SM; Jung Y; Yoon N; Kim TK; Kim K; Yang BM
PLoS One; 2018; 13(10):e0206121. PubMed ID: 30356251
[TBL] [Abstract][Full Text] [Related]
6. "Cost-effectiveness" estimates result in flawed decision-making in listing drugs for reimbursement.
West R; Borden EK; Collet JP; Rawson NS; Tonks RS
Can J Public Health; 2002; 93(6):421-5. PubMed ID: 12448863
[TBL] [Abstract][Full Text] [Related]
7. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
8. Decision analysis for resource allocation in health care.
Griffin S; Claxton K; Sculpher M
J Health Serv Res Policy; 2008 Oct; 13 Suppl 3():23-30. PubMed ID: 18806189
[TBL] [Abstract][Full Text] [Related]
9. Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making.
Franken M; Nilsson F; Sandmann F; de Boer A; Koopmanschap M
Pharmacoeconomics; 2013 Sep; 31(9):781-97. PubMed ID: 23839699
[TBL] [Abstract][Full Text] [Related]
10. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
11. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
13. Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer.
McCullagh L; Schmitz S; Barry M; Walsh C
Pharmacoeconomics; 2017 Nov; 35(11):1177-1185. PubMed ID: 28770453
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
15. Value of Information Analysis for Research Decisions-An Introduction: Report 1 of the ISPOR Value of Information Analysis Emerging Good Practices Task Force.
Fenwick E; Steuten L; Knies S; Ghabri S; Basu A; Murray JF; Koffijberg HE; Strong M; Sanders Schmidler GD; Rothery C
Value Health; 2020 Feb; 23(2):139-150. PubMed ID: 32113617
[TBL] [Abstract][Full Text] [Related]
16. Value of information and value of implementation: application of an analytic framework to inform resource allocation decisions in metastatic hormone-refractory prostate cancer.
Hoomans T; Fenwick EA; Palmer S; Claxton K
Value Health; 2009; 12(2):315-24. PubMed ID: 18657098
[TBL] [Abstract][Full Text] [Related]
17. A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme.
Claxton K; Ginnelly L; Sculpher M; Philips Z; Palmer S
Health Technol Assess; 2004 Jul; 8(31):1-103, iii. PubMed ID: 15248937
[TBL] [Abstract][Full Text] [Related]
18. Why is There Discordance between the Reimbursement of High-Cost 'Life-Extending' Pharmaceuticals and Medical Devices? The Funding of Ventricular Assist Devices in Australia.
Saing S; van der Linden N; Hayward C; Goodall S
Appl Health Econ Health Policy; 2019 Aug; 17(4):421-431. PubMed ID: 30906972
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
[TBL] [Abstract][Full Text] [Related]
20. Generalisability in economic evaluation studies in healthcare: a review and case studies.
Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
